Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Serina Therapeutics (SER) Divestments (2018 - 2021)

Serina Therapeutics' Divestments history spans 3 years, with the latest figure at -$516000.0 for Q4 2021.

On a quarterly basis, Divestments changed N/A to -$516000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was -$50000.0, a N/A change, with the full-year FY2021 number at -$50000.0, changed N/A from a year prior.
Divestments hit -$516000.0 in Q4 2021 for Serina Therapeutics, down from $516000.0 in the prior quarter.
Over the last five years, Divestments for SER hit a ceiling of $3.2 million in Q1 2018 and a floor of -$516000.0 in Q4 2021.
Historically, Divestments has averaged $648400.0 across 3 years, with a median of $77000.0 in 2019.